Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 4(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05781243Phase 4Completed

Normal Saline Versus Lactated Ringer's Solution for Acute Pancreatitis Resuscitation

Role: collaborator

NCT04850417Phase 4Not Yet Recruiting

Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection

Role: collaborator

NCT04357808Phase 2Completed

Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)

Role: collaborator

NCT03167424Unknown

Restenosis Intrastent: Treatment of Bioresorbable Vascular Scaffolds Restenosis

Role: collaborator

NCT03069066Phase 4Unknown

Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment With Scoring Balloon Pre-dilatation (RIBS VI Scoring)

Role: collaborator

NCT02672878Phase 4Unknown

Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)

Role: collaborator

All 6 trials loaded